Tissue Regenix Group PLC on Tuesday said it has signed an exclusive distribution deal with 2med GmbH, a Hamburg-based service provider for surgical and ortho-biological treatments of the musculoskeletal system.

The Leeds, England-based medical device company said that the multiyear agreement, which is for the distribution of OrthoPure XT in Germany, could potentially be extended into other regions covered by 2med representatives.

OrthoPure XT is a non-human biologic graft, which can be used for the revision of anterior cruciate ligament reconstruction, or ACL, procedures, as well as the reconstruction of other knee ligaments.

2med is an independent specialist dealer of surgical and biological therapy procedures for shoulders, knees, feet and ankles.

‘Following the success of our partnership with Geistlich Biomaterials Italia, that we announced in March 2022, we are pleased to have signed this distribution agreement with 2med for Germany,’ said Chief Executive Officer Daniel Lee.

‘2med’s work with doctors and patients, to offer advanced treatments and minimise rehabilitation times, are aligned with this innovative product and has made 2med one of the leading specialist dealers in Germany. We look forward to working with 2med and continuing to expand the use of OrthoPure XT across Europe.’

Tissue Regenix shares were trading 2.1% lower at 0.60 pence each in London on Tuesday afternoon.

Copyright 2022 Alliance News Limited. All Rights Reserved.